Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Travoprost + timolol + brinzolamide is a combination ophthalmic therapy used for the treatment of open-angle glaucoma and ocular hypertension. This regimen combines three agents with complementary mechanisms to lower intraocular pressure (IOP): travoprost, a prostaglandin F2α analog that increases uveoscleral outflow; timolol, a non-selective beta-adrenergic antagonist that reduces aqueous humor production; and brinzolamide, a carbonic anhydrase inhibitor that also decreases aqueous humor secretion. The triple combination is typically used in patients who require greater IOP reduction than can be achieved with monotherapy or dual therapy alone. Clinical studies have shown that adding brinzolamide to fixed-combination travoprost/timolol further lowers IOP compared to dual combinations or monotherapies[5]. This approach may improve adherence by reducing the number of separate eye drops required.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on travoprost + timolol + brinzolamide.